Milestone Pharmaceuticals (MIST) Work In Process (2025 - 2026)
Milestone Pharmaceuticals' (MIST) quarterly Work In Process came in at $4.3 million in Q2 2026, up 169.37% quarter-over-quarter from $1.6 million in Q1 2026.
Powered by 
Analysis
Milestone Pharmaceuticals (MIST) Work In Process (2025 - 2026) Analysis & Trends
Milestone Pharmaceuticals (MIST) has reported Work In Process for 2 consecutive years, with $4.3 million the latest figure, recorded in Q2 2026.
- For the quarter ending Q2 2026, Work In Process changed N/A year-over-year to $4.3 million; the trailing twelve-month figure through Jun 2026 stood at $4.3 million (changed N/A YoY), and the FY2025 full-year result was $521000.0, changed N/A from the prior year.
- Work In Process advanced to $4.3 million in Q2 2026 per MIST's latest filing, from $1.6 million in the prior quarter.
- Across five years, Work In Process topped out at $4.3 million in Q2 2026 and bottomed at $521000.0 in Q4 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Amgen | 206.44 Bn | 192.45 Bn | 7.24 Bn |
| 2 | Gilead Sciences | 179.97 Bn | 176.79 Bn | 6.22 Bn |
| 3 | Vertex Pharmaceuticals | 130.57 Bn | 122.72 Bn | 2.84 Bn |
| 4 | Regeneron Pharmaceuticals | 81.63 Bn | 73.63 Bn | 3.93 Bn |
| 5 | Argenx Se | 60.34 Bn | 55.16 Bn | 1.37 Bn |
| 6 | Moderna | 54.37 Bn | 49.23 Bn | 52.00 Mn |
| 7 | Alnylam Pharmaceuticals | 33.07 Bn | 29.76 Bn | 992.69 Mn |
| 8 | Biogen | 31.84 Bn | 30.55 Bn | 1.96 Bn |
| 9 | Roivant Sciences | 29.49 Bn | 29.49 Bn | 1.16 Mn |
| 10 | Milestone Pharmaceuticals | 146.32 Mn | -25.18 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 4.35 Mn |
| Mar 31, 2026 | 1.61 Mn |
| Dec 31, 2025 | 521,000.00 |